Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and tolerability of inhaled SLIT amikacin in cystic fibrosis with chronic Pseudomonas aeruginosa infection
2005-004389-17Phase 2Completed
- Sponsor
- Transave, Inc.
- Start
- Oct 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of amikacin in cystic fibrosis (CF) and Pseudomonal infection, sponsored by Transave, Inc. Primary endpoints: Safety and tolerability of SLIT amikacin and Change in Pseudomonas aeruginosa sputum density. Started Oct 2005; status: completed.
02
Drugs
amikacin
03
Conditions
cystic fibrosis (CF)Pseudomonal infection
Beyond the preview
Go deeper on 2005-004389-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-004389-17.